March 3: The Week in Cancer News
Exercising only 11 minutes per day can reduce your cancer risk, and new robotic technology helps detect early-stage lung cancer.
Progress Against Cancer
Exercising only 11 minutes per day can reduce your cancer risk, and new robotic technology helps detect early-stage lung cancer.
In the United States, about 40% of cancer cases are associated with preventable risk factors. According to the AACR Cancer Progress Report 2022, 15 types of cancer have been linked to being overweight or...
A study found women in California were more likely to have cervical cancer diagnoses at a later stage after age 65.
Aggressive end-of-life measures are common in people with advanced cancer in nursing homes, and more news selected by the editors of Cancer Today.
Drugs and mechanical ventilation appear to be effective in preventing potentially fatal damage to cardiovascular muscles, including those in the heart, after immune system is stimulated by immune checkpoint inhibitors. Doctors in France have...
More older women with breast cancer may not need radiation therapy, and more news from the week, selected by the editors of Cancer Today.
Patients with lung cancer who received an immune checkpoint inhibitor before surgery had improved long-term survival rates and lower rates of recurrence than historically observed, according to a study published in an AACR journal....
A drug that selectively targets cancer cells was approved for the treatment of certain HR-positive breast cancers. The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for patients with locally advanced...
Patients who receive certain forms of chemo face long-term risk for heart failure, and screening levels for certain cancers remain below expectations.
Guest Post by William G. Nelson, MD, PhD, Editor-in-Chief, Cancer Today Many argue that warfare metaphors, with winners and losers, may not be the best way to imagine the entirety of the cancer experience. With that...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More